BML Stock Overview
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland.
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||zł6.18|
|52 Week High||zł10.39|
|52 Week Low||zł2.72|
|1 Month Change||-21.27%|
|3 Month Change||69.78%|
|1 Year Change||-37.13%|
|3 Year Change||564.52%|
|5 Year Change||432.76%|
|Change since IPO||28.75%|
Recent News & Updates
|BML||PL Biotechs||PL Market|
Return vs Industry: BML exceeded the Polish Biotechs industry which returned -41.7% over the past year.
Return vs Market: BML underperformed the Polish Market which returned -33.1% over the past year.
|BML Average Weekly Movement||19.9%|
|Biotechs Industry Average Movement||10.5%|
|Market Average Movement||6.1%|
|10% most volatile stocks in PL Market||11.7%|
|10% least volatile stocks in PL Market||3.8%|
Stable Share Price: BML is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 20% a week.
Volatility Over Time: BML's weekly volatility has increased from 13% to 20% over the past year.
About the Company
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., a biotechnology company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50, a product used in treating superficial (non-muscle invasive) bladder tumour; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerol is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.
BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. Fundamentals Summary
|BML fundamental statistics|
Is BML overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BML income statement (TTM)|
|Cost of Revenue||zł35.60m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 09, 2022
|Earnings per share (EPS)||0.068|
|Net Profit Margin||10.17%|
How did BML perform over the long term?See historical performance and comparison